Billionaire David Harding is Buying These 5 Stocks

2. Myovant Sciences Ltd. (NYSE:MYOV)

Winton Capital Management’s Stake Value: $287,000

Percentage of Winton Capital Management’s 13F portfolio: 0.01%

Total Number of Hedge Fund Holders: 13

Myovant Sciences Ltd. (NYSE: MYOV) is next on David Harding’s radar, a growing biopharmaceutical company that deals in the development of  therapies for the treatment of women’s health and endocrine diseases.

By the end of September, the company reported an EPS of -$0.23, beating estimates by $0.17. For the third quarter, revenue stood at $77.90 million, surpassing expectations by $6.09 million.

In Q3 2021, 13 hedge funds out of 867 tracked by Insider Monkey disclosed ownership in Myovant Sciences Ltd. (NYSE: MYOV), with a combined value of $40.73 million. This is in comparison to the previous quarter where 18 hedge funds held $103.19 million worth of shares in the bio-pharmaceutical company.